000153096 001__ 153096
000153096 005__ 20250410160822.0
000153096 0247_ $$2doi$$a10.1038/s41541-025-01110-3
000153096 0248_ $$2sideral$$a143557
000153096 037__ $$aART-2025-143557
000153096 041__ $$aeng
000153096 100__ $$aFelgueres, María-José
000153096 245__ $$aCytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine
000153096 260__ $$c2025
000153096 5060_ $$aAccess copy available to the general public$$fUnrestricted
000153096 5203_ $$aInfection with Mycobacterium tuberculosis (Mtb) can produce a wide spectrum of clinical manifestations, ranging from active tuberculosis (TB) to asymptomatic latent infection. Although CD4 T-cells are key immune effectors to control TB, early after infection, the innate immune response must play a role in tackling the disease. Here, we performed in-depth analyses of the acute immune response to MTBVAC, a candidate vaccine engineered from Mtb with the aim of protecting adults from pulmonary TB disease, still a major global challenge. scRNA-seq shows expansion of CD4+ and cytotoxic γδ T-cells, data confirmed by flow cytometry. CD4 T-cells exhibited lower HLA-DR and higher L-selectin expression, compared to BCG-stimulation, indicating differential activation or dynamics. Importantly, MTBVAC-activated γδ T-cells had a unique cytotoxic CD16+GZMB+ phenotype, reminiscent of effector cells found in Mtb positive individuals controlling infection. IFN-γ and TNF-α were released in cultures, while IL-17A/F were almost undetectable.
000153096 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/RTC-2017-6379-1
000153096 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000153096 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000153096 700__ $$aEsteso, Gloria
000153096 700__ $$aGarcía-Jiménez, Álvaro F.
000153096 700__ $$aBenguría, Alberto
000153096 700__ $$aVázquez, Enrique
000153096 700__ $$0(orcid)0000-0001-7897-9173$$aAguiló, Nacho$$uUniversidad de Zaragoza
000153096 700__ $$aPuentes, Eugenia
000153096 700__ $$aDopazo, Ana
000153096 700__ $$aMurillo, Ingrid
000153096 700__ $$0(orcid)0000-0003-2993-5478$$aMartín, Carlos$$uUniversidad de Zaragoza
000153096 700__ $$aRodríguez, Esteban
000153096 700__ $$aReyburn, Hugh T.
000153096 700__ $$aValés-Gómez, Mar
000153096 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000153096 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000153096 773__ $$g10, 1 (2025), 58 [12 pp.]$$pnpj Vaccines$$tnpj Vaccines$$x2059-0105
000153096 8564_ $$s3774140$$uhttps://zaguan.unizar.es/record/153096/files/texto_completo.pdf$$yVersión publicada
000153096 8564_ $$s2712196$$uhttps://zaguan.unizar.es/record/153096/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000153096 909CO $$ooai:zaguan.unizar.es:153096$$particulos$$pdriver
000153096 951__ $$a2025-04-10-14:04:41
000153096 980__ $$aARTICLE